The Long-Term Prognostic Significance of 6-Minute Walk Test Distance in Patients with Chronic Heart Failure

Lee Ingle, John G. Cleland, and Andrew L. Clark

1 Department of Sport, Health & Exercise Science, University of Hull, 104 Don Building, Cottingham Road, Kingston upon Hull, HU7 6RX, UK
2 National Heart & Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College, London, UK
3 Department of Cardiology, Castle Hill Hospital, Kingston upon Hull, HU16 5JQ, UK

Correspondence should be addressed to Lee Ingle; l.ingle@hull.ac.uk

Received 4 November 2013; Accepted 26 February 2014; Published 27 March 2014

Background. The 6-minute walk test (6-MWT) is used to assess patients with chronic heart failure (CHF). The prognostic significance of the 6-MWT distance during long-term followup (>5 years) is unclear.

Methods. 1,667 patients (median [inter-quartile range, IQR]) (age 72 [65–77]; 75% males) with heart failure due to left ventricular systolic impairment undertook a 6-MWT as part of their baseline assessment and were followed up for 5 years. Results. At 5 years’ followup, those patients who died (n = 959) were older at baseline and had a higher log NT pro-BNP than those who survived to 5 years (n = 708). 6-MWT distance was lower in those who died [163 (153) m versus 269 (160) m; P < 0.0001]. Median 6-MWT distance was 300 (150–376) m, and quartile ranges were <46 m, 46–240 m, 241–360 m, and >360 m. 6-MWT distance was a predictor of all-cause mortality (HR 0.97; 95% CI 0.96-0.97; Chi-square = 184.1; P < 0.0001). Independent predictors of all-cause mortality were decreasing 6-MWT distance, increasing age, increasing NYHA classification, increasing log NT pro-BNP, decreasing diastolic blood pressure, decreasing sodium, and increasing urea.

Conclusion. The 6-MWT is an important independent predictor of all-cause mortality following long-term followup in patients with CHF.

1. Introduction

Functional capacity is strongly related to survival in patients with chronic heart failure (CHF) [1]. Although cardiopulmonary exercise testing (CPET) with metabolic gas exchange measurements is perhaps the “gold standard” method for assessing exercise capacity, it is not widely available, and so more simple tests are commonly used [2]. The 6-minute walk test (6-MWT) is reproducible and sensitive to changes in quality of life [3–5]. It is a self-paced, submaximal test, and exercise intensity mimics activities of daily living in patients with mild-to-moderate heart failure [6–9]. Thus, the 6-MWT may suit patients with CHF who may experience symptoms such as breathlessness below their peak exercise capacity.

We have previously reported that decreasing 6-MWT distance was an independent predictor of increasing mortality in patients with left ventricular systolic dysfunction but that it was a less potent single predictor than N-terminal pro-brain natriuretic peptide (NT pro-BNP) [10]. Others have shown that the 6-MWT distance is a less powerful predictor of outcome than some variables, such as VE/VCO2 slope and peak oxygen uptake derived from CPET [11].

The aim of the present study was to assess the long-term (>5 years) prognostic significance of the 6-MWT distance in a large sample of patients with CHF.

2. Methods

The Hull and East Riding Ethics Committee approved the study, and all patients provided informed consent for participation. Clinical information obtained included past medical history and drug and smoking history. Clinical examination included assessment of body mass index (BMI), heart rate, rhythm, and blood pressure (BP). Heart failure was defined as current symptoms of heart failure, or a history of symptoms controlled by ongoing therapy, in the presence of reduced left ventricular (LV) systolic function on echocardiography.
and in the absence of any other cause for symptoms [12, 13].
2D echocardiography was carried out by one of three trained
operators. LV function was assessed by estimation on a scale
of normal, mild, mild-to-moderate, moderate, moderate-to-
severe, and severe impairment. LV ejection fraction (LVEF)
was calculated using Simpson’s formula, where possible, from
measurements of end-diastolic and end-systolic volumes on
apical 2D views, following the guidelines of Schiller et al. [14]
and LVSD was diagnosed if LVEF was <45%.

The 6-MWT was conducted following a standardised
protocol [9, 10]. A 15 m flat, obstacle-free corridor, with chairs
placed at either end, was used. Patients were instructed to
walk as far as possible, turning 180° every 15 m in the allotted
time of 6 min. Patients were able to rest, if needed, and the
time remaining was called every second minute [15]. Patients
were excluded if they were unable to walk without assistance
from another person (not including mobility aids), or if they
were unable to exercise because of noncardiac limitations.
Patients walked unaccompanied so as not to influence walk-
ing speed. After 6 min, patients were instructed to stop and
the total distance covered was measured to the nearest metre.
Standardised verbal encouragement was given to patients
after 2 min and 4 min. If a patient could not undertake the
6-MWT, a distance of 0 m was recorded.

2.1. Statistical Analysis. Continuous variables are presented
as median with interquartile range (IQR) or standard
deviation (SD) and categorical data as percentages. Con-
tinuous variables were assessed for normality by the
Kolmogorov-Smirnov test. NT pro-BNP was normalised by
log-transformation for analysis. Differences between
those who survived to five years and those who did not
were determined by the independent samples t-test or
Pearson’s Chi-square test. No survivor was followed up for
less than 5 years. We used receiver operating characteristic
(ROC) curves to assess the predictive power of variables and
report the area under the curve (AUC) with 95% confidence
intervals (CI), sensitivity, specificity, and optimal cut-points.
To define the optimal cut-point, we used the point closest to
the upper left corner of the ROC curve, often known as the
(0, 1) criterion.

We used Kaplan-Meier curves to display mortality data
using the guidance of Pocock et al. [16]. For illustration, 6-
MWT distance data were divided into quartiles (<45 m, 46–
240 m, 241–360 m, and >360 m). Cox regression models (uni-
variable and multivariable) were used to develop predictor
models using all baseline variables. We used multivariable
Cox proportional hazards model using the backward like-
lihood ratio method (P value for entry was <0.05; P value
for removal was >0.1) to identify independent predictors of
all-cause mortality from candidate predictor variables. The
assumption of proportionality was tested for each variable
using the method of Grambsch and Therneau [17].

To minimise the risk of “overfitting,” we were guided
by Peduzzi and colleagues [18, 19] who suggested an events
per variable ratio of 10:1. To determine the robustness of
our model(s), we performed bootstrapping based on 1,000
stratified samples. We checked for colinearity by calculating
Pearson correlation coefficients. We used a cut-off value of
0.3 to identify collinearity. SPSS version 19.0 (IBM, New York,
USA) was used to analyse the data. An arbitrary level of 5%
statistical significance was used throughout (two-tailed).
We followed the guidance of Perneger [20] and did not adjust for
multiple testing in order to avoid the inflation of type I error.
The primary outcome measure was all-cause mortality.

3. Results

1,667 patients (median (interquartile range, IQR)) (age 72
(65–77); 75% males) with heart failure due to left ventricular
systolic impairment were included in the study. At 5-year
followup, those patients who died (n = 959) were, at
baseline, older and had a lower BMI, higher NYHA class,
lower LVEF, higher creatinine, higher log NT pro-BNP, lower
haemoglobin, and higher urea levels than those who survived
to 5 years (n = 708; Table 1). 6-MWT distance was lower
in those who died (163 (153) m versus 269 (160) m; P
< 0.0001). Median 6-MWT distance was 300 (150–376) m,
and quartile ranges for 6-MWT distance were <46 m, 46–240 m,
241–360 m, and >360 m. Table 2 shows clinical characteristics
divided by quartiles of 6-MWT distance. There were signif-
icant between-group differences for age, BMI, LVEF, resting
HR, resting systolic/diastolic BP, QRS duration, haemoglobin,
log NT pro-BNP, urea, and creatinine (all P < 0.05).

Thirteen variables were significantly associated with all-
cause mortality in univariable Cox analysis (Table 3). After
bootstrapping, only 6 variables (6-MWT; age, NT pro-
BNP, NYHA class, diastolic BP, and haemoglobin) remained
statistically significant (Table 4). All variables in Table 1 were
included in a final multivariable Cox model, and six were
independent predictors of all-cause mortality, decreasing 6-
MWT distance, increasing age, increasing NYHA classifica-
tion, increasing NT pro-BNP, decreasing diastolic blood pres-
sure, decreasing sodium, and increasing urea (Table 5). ROC
curve analysis of 6-MWT distance and all-cause mortality at
5 years is shown in Figure 1 (AUC = 0.67; P < 0.0001; 95%
CI = 0.64–0.70; the optimal cut-point for 6-MWT distance
was 350 m with sensitivity 0.81 and specificity 0.57). Figure 2
shows a Kaplan-Meier survival curve for the patients divided
by quartiles of 6-MWT distance (<46 m: event free survival
24%; 46–240 m: event free survival 29%; 241–360 m: event
free survival 45%; >360 m: event free survival 70%).

4. Discussion

We have shown that the 6-MWT is an independent predictor
of all-cause mortality during long-term (5 year) followup
in patients with CHF. To our knowledge, this is the largest
study that has focused on the prognostic value of 6-MWT distance
during extended followup. We have previously shown that 6-
MWT distance is an independent predictor of risk following
medium-term followup (median 36.6 (28–45) months). In
1,592 patients, 212 died representing a crude death rate of
13.3%. Five independent predictors of all-cause mortality
were identified including decreasing 6-MWT distance [10].

Other large-scale studies including the SENIORS trial [21]
(n = 2, 128 patients, ≥70 years with LVEF ≤ 35% or recent
hospital admission) have also shown that 6-MWT distance

BioMed Research International
Table 1: Baseline characteristics of patients [mean (SD)] divided by survival to >5 years.

| Variables                          | Dead (n = 959) | Alive (n = 708) | P value |
|------------------------------------|----------------|-----------------|---------|
| Age (years)                        | 74.1 (8.9)     | 67.9 (10.6)     | <0.0001 |
| Males (%)                          | 73             | 75              | 0.184   |
| BMI (kg m⁻²)                       | 27.7 (5.7)     | 28.9 (5.6)      | <0.0001 |
| NYHA class                         |                |                 |         |
| I/II                               | 36             | 64              | <0.0001 |
| III/IV                             | 58             | 42              |         |
| LVEF (%)                           | 33 (10)        | 36 (9)          | <0.0001 |
| FEV₁/FVC (%)                       | 66 (16)        | 70 (16)         | <0.0001 |
| Resting HR (beats·min⁻¹)           | 76 (18)        | 74 (20)         | 0.165   |
| Resting systolic BP (mmHg)         | 132 (26)       | 133 (24)        | 0.158   |
| Resting diastolic BP (mmHg)        | 74 (14)        | 78 (14)         | <0.0001 |
| QRS duration (ms)                  | 121 (32)       | 112 (29)        | <0.0001 |
| Haemoglobin (g·dL⁻¹)               | 13.0 (1.7)     | 13.9 (1.5)      | <0.0001 |
| Log NT pro-BNP*                    | 7.7 (1.2)      | 6.7 (1.3)       | <0.0001 |
| Sodium (mmol·L⁻¹)                  | 139 (4)        | 139 (3)         | 0.652   |
| Potassium (mmol·L⁻¹)               | 4.4 (0.5)      | 4.4 (0.5)       | 0.777   |
| Urea (mmol·L⁻¹)                    | 9.3 (4.7)      | 7.1 (3.6)       | <0.0001 |
| Creatinine (u·mL⁻¹)                | 130 (51)       | 110 (55)        | <0.0001 |
| Diuretic (%)                       | 83             | 84              | 0.760   |
| ACE-inhibitor (%)                  | 78             | 77              | 0.348   |
| Beta-blocker (%)                   | 73             | 69              | 0.322   |
| Spironolactone (%)                 | 22             | 20              | 0.202   |
| 6-MWT (m)                          | 163 (153)      | 269 (160)       | <0.0001 |

NYHA: New York Heart Association; BMI: body mass index; LVEF: left ventricular ejection fraction available in 67% of patients; 6-MWT: 6-min walk test; log NT pro-BNP (pg·mL⁻¹) * available in 92% of patients.

Table 2: Clinical characteristics separated by quartiles of 6-MWT distance in patients with CHF (mean ± SD).

| Variables                          | ≤45 m          | 46–240 m       | 241–360 m       | >360 m       | P value |
|------------------------------------|----------------|----------------|----------------|--------------|---------|
| Age (years)                        | 72.4 (10.6)    | 72.9 (9.6)     | 71.3 (8.8)     | 64.9 (10.6)  | <0.0001 |
| BMI (kg·m⁻²)                       | 27.5 (4.5)     | 27.7 (5.2)     | 28.5 (5.8)     | 28.9 (6.8)   | 0.002   |
| LVEF (%)                           | 32.0 (10.0)    | 35.1 (10.7)    | 34.6 (9.2)     | 36.2 (9.3)   | <0.0001 |
| FEV₁/FVC (%)                       | 66.4 (17.7)    | 67.5 (15.0)    | 67.3 (16.5)    | 68.8 (16.4)  | 0.257   |
| Resting HR (beats·min⁻¹)           | 80 (36)        | 75 (17)        | 73 (17)        | 72 (17)      | <0.0001 |
| Resting systolic BP (mmHg)         | 129 (29)       | 134 (25)       | 136 (23)       | 135 (23)     | <0.0001 |
| Resting diastolic BP (mmHg)        | 74 (14)        | 77 (15)        | 77 (14)        | 80 (14)      | <0.0001 |
| QRS duration (ms)                  | 117 (31)       | 119 (33)       | 120 (32)       | 114 (30)     | 0.045   |
| Haemoglobin (g·dL⁻¹)               | 13.0 (1.9)     | 13.2 (1.7)     | 13.6 (1.5)     | 14.1 (1.4)   | <0.0001 |
| Log NT pro-BNP                     | 7.5 (1.4)      | 7.3 (1.4)      | 7.0 (1.2)      | 6.5 (1.3)    | <0.0001 |
| Sodium (mmol·L⁻¹)                  | 138 (3.9)      | 139 (3.8)      | 139 (3.3)      | 139 (3.0)    | 0.241   |
| Potassium (mmol·L⁻¹)               | 4.4 (0.6)      | 4.4 (0.5)      | 4.4 (0.5)      | 4.4 (0.5)    | 0.382   |
| Urea (mmol·L⁻¹)                    | 9.2 (5.0)      | 8.5 (4.7)      | 7.9 (3.9)      | 6.7 (3.8)    | <0.0001 |
| Creatinine (u·mL⁻¹)                | 125 (52)       | 121 (49)       | 116 (44)       | 107 (65)     | <0.0001 |

is an independent predictor of mortality over a modest time period (mean followup: 21 months) [21]. Another study [22] (mean followup 34 months) has also confirmed the prognostic value of 6-MWT distance for predicting cardiac-related death in patients with mild-to-moderate CHF. Long-term studies have been reported in patients with stable coronary heart disease, including the Heart and Soul Study [23] which followed up patients for a median of 8.0 (4.2–9.0) years and showed that 6-MWT distance predicted cardiovascular events and provided similar prognostic value to treadmill exercise capacity. A limitation of the study was a small sample size (n = 556) and a limited number of events (184 deaths).

A number of studies have shown that 6-MWT distance is a less powerful predictor of outcome in patients with CHF than variables derived from CPET such as VE/VCO₂ slope and peak oxygen uptake [24]. Opasich and colleagues [25]...
### Table 3: Unadjusted univariable predictors of all-cause mortality in patients with CHF (in order of Chi-square value).

| Variables                        | $P$ value | HR     | 95% CI      | Chi-square |
|----------------------------------|-----------|--------|-------------|------------|
| Log NT pro-BNP                  | <0.0001   | 1.63   | 1.53 - 1.74 | 230.8      |
| 6-MWT (m)*                      | <0.0001   | 0.968  | 0.964 - 0.973 | 184.1      |
| Age (years)                     | <0.0001   | 1.05   | 1.04 - 1.06 | 137.2      |
| Urea (mmol·L$^{-1}$)            | <0.0001   | 1.05   | 1.05 - 1.06 | 128.9      |
| Haemoglobin (g·dL$^{-1}$)       | <0.001    | 0.84   | 0.81 - 0.87 | 96.9       |
| NYHA class                      | <0.0001   | 1.64   | 1.48 - 1.82 | 89.0       |
| Creatinine (μ·mol$^{-1}$)*      | <0.001    | 1.023  | 1.016 - 1.029 | 58.3      |
| Diastolic BP (mmHg)             | <0.001    | 0.99   | 0.98 - 0.99 | 42.4       |
| Sodium (mmol·L$^{-1}$)          | <0.001    | 0.96   | 0.94 - 0.97 | 27.1       |
| QRS duration (ms)*             | <0.001    | 1.05   | 1.03 - 1.07 | 18.3       |
| BMI (kg·m$^{-2}$)               | <0.001    | 0.98   | 0.97 - 0.99 | 14.6       |
| Systolic BP (mmHg)              | <0.001    | 1.00   | 0.99 - 1.00 | 8.9        |
| Heart rate (beats·min$^{-1}$)   | 0.01      | 1.00   | 1.00 - 1.01 | 7.1        |

HR: hazard ratio; 95% CI: 95% confidence intervals; 6-MWT: 6-minute walk test; NYHA: New York Heart Association; LVI: left ventricular impairment; * HR reported for 10-unit increment.

### Table 4: Bootstrap model based on 1000 stratified samples. Univariable predictors listed in order of magnitude of $P$ value.

| Variables                        | $B$      | Bias     | SE    | $P$ value | 95% CI      |
|----------------------------------|----------|----------|-------|-----------|-------------|
| Log NT pro-BNP                  | 0.489    | −0.001   | 0.35  | 0.001     | 0.418 - 0.556 |
| 6-MWT (m)*                      | −0.002   | 0.0001   | 0.0001 | 0.001     | −0.002 - −0.001 |
| Age (years)                     | 0.042    | −0.001   | 0.004 | 0.001     | 0.033 - 0.050 |
| NYHA class                      | 0.136    | 0.004    | 0.060 | 0.023     | 0.027 - 0.263 |
| Diastolic BP (mmHg)             | −0.007   | 0.0001   | 0.003 | 0.030     | −0.013 - −0.001 |
| Haemoglobin (g·dL$^{-1}$)       | −0.041   | −0.002   | 0.021 | 0.049     | −0.082 - 0.002 |
| Urea (mmol·L$^{-1}$)            | 0.024    | −0.002   | 0.014 | 0.068     | −0.006 - 0.047 |
| Sodium (mmol·L$^{-1}$)          | −0.014   | −0.001   | 0.010 | 0.182     | −0.034 - 0.007 |
| QRS duration (ms$^{-1}$)        | 0.001    | 0.0001   | 0.001 | 0.253     | −0.001 - 0.004 |
| Systolic BP (mmHg)              | 0.001    | 0.0001   | 0.002 | 0.528     | −0.002 - 0.005 |
| Creatinine (μ·mol$^{-1}$)       | 0.001    | 0.0001   | 0.001 | 0.667     | −0.001 - 0.004 |
| Heart rate (beats·min$^{-1}$)   | 0.000    | 0.0001   | 0.002 | 0.736     | −0.002 - 0.005 |
| Potassium (mmol·L$^{-1}$)       | −0.001   | 0.0001   | 0.073 | 0.982     | −0.143 - 0.137 |

SE: standard error; 95% CI: 95% confidence intervals; 6-MWT: 6-minute walk test; NYHA: New York Heart Association; LVI: left ventricular impairment.

### Table 5: Multivariable predictors of long-term all-cause mortality in patients with CHF: final model (listed in order of magnitude of Wald statistic).

| Variables                        | $P$ value | Wald | HR     | 95% CI   |
|----------------------------------|-----------|------|--------|----------|
| Log NT pro-BNP                  | <0.0001   | 86.3 | 1.393  | 1.299 - 1.494 |
| 6-MWT (m)*                      | <0.0001   | 57.2 | 0.980  | 0.974 - 0.985 |
| Age (years)                     | <0.0001   | 29.9 | 1.026  | 1.017 - 1.036 |
| Diastolic BP (mmHg)             | 0.001     | 12.8 | 0.990  | 0.984 - 0.995 |
| Urea (mmol·L$^{-1}$)            | 0.002     | 9.5  | 0.980  | 0.974 - 0.985 |
| Sodium (mmol·L$^{-1}$)          | 0.052     | 3.8  | 0.978  | 0.957 - 1.000 |

HR: hazard ratio; 95% CI: 95% confidence intervals; 6-MWT: 6-minute walk test; NYHA: New York Heart Association; * HR reported for 10-unit increment.
1.0
0.8
0.6
0.4
0.2
0.0
Sensitivity
1−
specificity
Figure 1: Receiver operating characteristic curve showing value of the 6-MWT for predicting all-cause mortality at 5 years in patients with CHF (AUC = 0.67; \(P < 0.0001\); 95% CI = 0.64–0.70; sensitivity = 0.81; specificity = 0.57; optimal cut-point = 350 m).

1.0
0.8
0.6
0.4
0.2
0.0
Cum. survival
Time (years)
>360 m

241–360 m

46–240 m

<46 m
Log-rank mantel Cox
\(\chi^2 = 16.0; P \leq 0.0001\)
\(\chi^2 = 72.7; P \leq 0.0001\)
\(\chi^2 = 235.6; P \leq 0.0001\)
Figure 2: Kaplan-Meier survival curve showing quartiles of 6-MWT distance (m) (<46 m, event free survival 24%; 46–240 m, event free survival 29%; 241–360 m, event free survival 45%; >360 m, event free survival 70%).

concluded that 6-MWT distance (mean followup 387 ± 177 days) does not provide complimentary prognostic information or should be substituted for peak oxygen consumption. In a study of only 253 patients with either systolic or diastolic heart failure in whom there were 43 cardiac events over 4 years, Guazzi et al. [11] found that although 6-MWT distance correlated with peak oxygen uptake and VE/VCO₂ slope, there was no significant association between 6-MWT distance and survival. However, CPET-derived variables were predictors of prognosis.

Most studies using CPET variables as potential predictors of outcome have followed up patients for two years or less. Studies have reported very short-term (e.g., 6 months or less) followup [26, 27], 12 months [28–31] or up to 2 years [26, 32–37]. Few studies have reported tracking periods beyond 3 years [38, 39]. Prognostic models for patients with heart failure usually contain variables from domains measuring some aspect of exercise capacity, some indicator of cardiac function (such as left ventricular ejection fraction), and some indicator of systemic involvement (such as creatinine). CPET is not widely available. We show here that the simple and cheap 6-MWT distance is an easily obtainable variable which strongly relates to long-term survival in patients with CHF.

4.1. Study Limitations. The 6-MWT is not a test of maximal exercise capacity but is a test of submaximal exercise performance [6]. The American Thoracic Society [7] advocates that verbal encouragement should be limited and tone of voice be controlled during the 6-MWT in an elderly, chronic disease population. We have followed this approach with our patients but different centres will operate different systems. Therefore, findings from our current study should not be extrapolated to other populations or to other research centres that may use a more aggressive 6-MWT coaching style.

4.2. Conclusion. The 6-MWT is an independent predictor of all-cause mortality following long-term (5-year) followup in patients with CHF. It provides similar or better discriminatory power than other routinely collected physical and biochemical variables and, as such, might make a reasonable target for treatment.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] C. Schalcher, H. Rickli, M. Brehm et al., “Prolonged oxygen uptake kinetics during low-intensity exercise are related to poor prognosis in patients with mild-to-moderate congestive heart failure,” Chest, vol. 124, no. 2, pp. 580–586, 2003.
[2] M. Guazzi, V. Adams, V. Conraads et al., “EACPR/AHA scientific statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations,” Circulation, vol. 126, no. 18, pp. 2261–2274, 2012.
[3] L. Ingle, R. J. Shelton, A. S. Rigby, S. Nabb, A. L. Clark, and J. G. F. Cledand, “The reproducibility and sensitivity of the 6-min walk test in elderly patients with chronic heart failure,” European Heart Journal, vol. 26, no. 17, pp. 1742–1751, 2005.
[4] D. P. Lipkin, A. J. Scriven, T. Crake, and P. A. Poole-Wilson, “Six minute walking test for assessing exercise capacity in chronic heart failure,” British Medical Journal, vol. 292, no. 6521, pp. 653–655, 1986.
[5] L. G. Olsson, K. Swedberg, A. L. Clark, K. K. Witte, and J. G. F. Cleland, “Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review,” *European Heart Journal*, vol. 26, no. 8, pp. 778–793, 2005.

[6] L. Ingle, M. Wilkinson, S. Carroll et al., “Cardiorespiratory requirements of the 6-min walk test in older patients with left ventricular systolic dysfunction and no major structural heart disease,” *International Journal of Sports Medicine*, vol. 28, no. 8, pp. 678–684, 2007.

[7] R. O. Crapo, R. Casaburi, A. L. Coates et al., “ATS statement: guidelines for the six-minute walk test,” *American Journal of Respiratory and Critical Care Medicine*, vol. 166, no. 1, pp. 111–117, 2002.

[8] V. Bittner, D. H. Weiner, S. Yusuf et al., “Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction,” *Journal of the American Medical Association*, vol. 270, no. 14, pp. 1702–1707, 1993.

[9] L. Ingle, K. Goode, A. S. R. Rigby, J. G. F. Cleland, and A. L. Clark, “Predicting peak oxygen uptake from 6-min walk test performance in male patients with left ventricular systolic dysfunction,” *European Journal of Heart Failure*, vol. 8, no. 2, pp. 198–202, 2006.

[10] P. Peduzzi, J. Concato, A. R. Feinstein, and T. R. Holford, “Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates,” *Journal of Clinical Epidemiology*, vol. 48, no. 12, pp. 1503–1510, 1995.

[11] T. V. Perneger, “What's wrong with Bonferroni adjustments?,” *British Medical Journal*, vol. 316, no. 7139, pp. 1236–1238, 1998.

[12] L. Manzano, D. Babalis, M. Roughton et al., “Predictors of clinical outcomes in elderly patients with heart failure,” *European Journal of Heart Failure*, vol. 13, no. 5, pp. 528–536, 2011.

[13] L. J. Remme and K. Swedberg, “Comprehensive guidelines for the diagnosis and treatment of chronic heart failure: task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology,” *European Journal of Heart Failure*, vol. 4, no. 1, pp. 11–22, 2002.

[14] N. B. Schiller, P. M. Shah, M. Crawford et al., “Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms,” *Journal of the American Society of Echocardiography*, vol. 2, no. 5, pp. 358–367, 1989.

[15] V. Bittner, D. H. Weiner, S. Yusuf et al., “Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction,” *Journal of the American Medical Association*, vol. 270, no. 14, pp. 1702–1707, 1993.

[16] S. J. Pocock, T. C. Clayton, and D. G. Altman, “Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls,” *The Lancet*, vol. 359, no. 9318, pp. 1686–1689, 2002.

[17] P. M. Grambsch and T. M. Therneau, “Proportional hazards tests and diagnostics based on weighted residuals,” *Biometrika*, vol. 81, no. 3, pp. 515–526, 1994.

[18] E. W. Steyerberg, M. J. C. Eijkemans, F. E. Harrell Jr., and J. D. F. Habbema, “Prognostic modeling with logistic regression analysis: in search of a sensible strategy in small data sets,” *Medical Decision Making*, vol. 21, no. 1, pp. 45–56, 2001.

[19] L. Ingle, M. Wilkinson, S. Carroll et al., “Cardiorespiratory requirements of the 6-min walk test in older patients with left ventricular systolic dysfunction and no major structural heart disease,” *International Journal of Sports Medicine*, vol. 28, no. 8, pp. 678–684, 2007.

[20] R. O. Crapo, R. Casaburi, A. L. Coates et al., “ATS statement: guidelines for the six-minute walk test,” *American Journal of Respiratory and Critical Care Medicine*, vol. 166, no. 1, pp. 111–117, 2002.

[21] A. K. Gitt, K. Wissmar, and M. A. Peberdy, “Prognostic ability of VE/VCO2 slope calculations using different exercise test time intervals in subjects with heart failure,” *European Journal of Cardiovascular Prevention and Rehabilitation*, vol. 10, no. 6, pp. 463–468, 2003.

[22] R. Arena, J. Myers, M. A. Peberdy, and R. A. Holldorff, “Apical function and the VE/VCO2 slope as a predictor of outcome in patients with heart failure,” *Journal of Cardiopulmonary Rehabilitation*, vol. 24, no. 5, pp. 317–320, 2004.

[23] R. Arena, J. Myers, J. Abella et al., “Development of a ventilatory classification system in patients with heart failure,” *Circulation*, vol. 115, no. 18, pp. 2410–2417, 2007.

[24] M. Guazzi, J. Myers, M. A. Peberdy, and R. A. Holldorff, “Apical function and the VE/VCO2 slope as a predictor of outcome in patients with heart failure,” *Journal of Cardiopulmonary Rehabilitation*, vol. 24, no. 5, pp. 317–320, 2004.

[25] R. Arena, J. Myers, J. Abella et al., “Development of a ventilatory classification system in patients with heart failure,” *Circulation*, vol. 115, no. 18, pp. 2410–2417, 2007.

[26] M. Guazzi, J. Myers, M. A. Peberdy, and R. A. Holldorff, “Apical function and the VE/VCO2 slope as a predictor of outcome in patients with heart failure,” *Journal of Cardiopulmonary Rehabilitation*, vol. 24, no. 5, pp. 317–320, 2004.

[27] R. Arena, J. Myers, M. A. Peberdy, and R. A. Holldorff, “Apical function and the VE/VCO2 slope as a predictor of outcome in patients with heart failure,” *Journal of Cardiopulmonary Rehabilitation*, vol. 24, no. 5, pp. 317–320, 2004.
[34] C. Scharf, T. Merz, W. Kiowski, E. Oechslin, C. Schalcher, and H. P. Brunner-La Rocca, "Noninvasive assessment of cardiac pumping capacity during exercise predicts prognosis in patients with congestive heart failure," Chest, vol. 122, no. 4, pp. 1333–1339, 2002.

[35] M. Cicoira, C. H. Davos, D. P. Francis et al., "Prediction of mortality in chronic heart failure from peak oxygen consumption adjusted for either body weight or lean tissue," Journal of Cardiac Failure, vol. 10, no. 5, pp. 421–426, 2004.

[36] T. P. Chua, P. Ponikowski, D. Harrington et al., "Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure," Journal of the American College of Cardiology, vol. 29, no. 7, pp. 1585–1590, 1997.

[37] D. P. Francis, W. Shamim, L. C. Davies et al., "Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO₂ slope and peak VO₂," European Heart Journal, vol. 21, no. 2, pp. 154–161, 2000.

[38] L. Ingle, K. K. Witte, J. G. J. F. Cleland, and A. L. Clark, "The prognostic value of cardiopulmonary exercise testing with a peak respiratory exchange ratio of < 1.0 in patients with chronic heart failure," International Journal of Cardiology, vol. 127, no. 1, pp. 88–92, 2008.

[39] L. C. Davies, D. P. Francis, M. Piepoli, A. C. Scott, P. Ponikowski, and A. J. S. Coats, "Chronic heart failure in the elderly: value of cardiopulmonary exercise testing in risk stratification," Heart, vol. 83, no. 2, pp. 147–151, 2000.